Background. The role played by airway infections with Pseudomonas aeruginosa in the course and pathogenesis of chronic obstructive pulmonary disease (COPD) has not yet been resolved. We report on the molecular epidemiology and population biology of P. aeruginosa in COPD.
severe exacerbations [10] [11] [12] [13] . The presence of P. aeruginosa in the lower airways is associated with symptoms of exacerbations [14] . When the same P. aeruginosa clone was isolated from a patient's airways over many years, the clone was found to diversify, which led to the coexistence of isolates with different morphotypes and antibiotic susceptibilities [15] . These and other observations indicate that P. aeruginosa is important in the setting of COPD.
In a recent prospective study, we further characterized the role played by P. aeruginosa in COPD [16] . Over the course of a 10-year study in which cultures of sputum were performed monthly, 39 of 126 adults with COPD acquired P. aeruginosa 1 or more times. The acquisition of a new strain of P. aeruginosa was associated with clinical symptoms of an exacerbation. Two distinct patterns of carriage of P. aeruginosa in the respiratory tracts of adults with COPD were observed: (1) short-term colonization followed by clearance of the strain and (2) persistence of the strain. The development of serum antibody responses occurred more often during long-term persistence than during shortterm carriage, but these antibody responses were not associated with clearance of the strains.
The recent prospective study [16] gathered basic data on the clinical significance of P. aeruginosa in the course of COPD. Next, we wanted to resolve the as-yet unknown population biology of P. aeruginosa in the lungs of those with COPD. By genotyping sequential isolates collected in a 10-year prospective study involving adults with COPD, the turnover, persistence, and microevolution of P. aeruginosa clones in airways of those with COPD were determined. The population structure of P. aeruginosa in COPD was compared with that of isolates from patients who received mechanical ventilation and from patients with CF who had chronic P. aeruginosa infection.
SUBJECTS AND METHODS

Study population.
A total of 126 patients with COPD were enrolled in a prospective study between April 1994 and December 2004 at the Buffalo Veterans Affairs Medical Center [16] [17] [18] . The Human Studies Subcommittee of the Veterans Affairs Western New York Healthcare System approved the study protocol. All participants provided written informed consent. Patients were seen monthly and whenever they had symptoms suggestive of an exacerbation. Sputum samples. Spontaneously expectorated morning sputum samples were obtained for microbiological analysis at each clinical visit and were processed promptly in the study clinic laboratory. Samples were homogenized by incubation at 37ЊC for 15 min with an equal volume of 0.1% dithiothreitol. Quantitative cultures were performed by plating serial dilutions of 1:10, 1:100, and 1:1000 in phosphate-buffered saline on blood, chocolate, and MacConkey agar plates. This method detects concentrations of 10 3 colony-forming units/mL of sputum. An isolate was identified as P. aeruginosa on the basis of colony morphology, absence of lactose fermentation, presence of oxidase, and MicroScan analysis using the Negative Urine Combo Panel Type 33 (Dade Behring). The presence or absence of a mucoid phenotype on Pseudomonas isolation agar plates was recorded for each isolate. Isolates were stored in Mueller-Hinton broth plus 10% (vol/vol) glycerol at Ϫ80ЊC.
After the aliquots of the homogenized sputum sample were removed for culture, the remainder of the sputum sample was centrifuged at 27,000 g for 30 min at 4ЊC. The supernatant was removed, and the pellet was mixed with 1 mL of buffer containing 0.01 mol/L Tris, 0.15 mol/L NaCl, and 15% glycerol (pH 7.4). Supernatant and pellet were stored separately at Ϫ80ЊC. Pellets were analyzed by polymerase chain reaction (PCR) for the presence of the P. aeruginosa gene oprF [16] .
The adequacy of expectorated sputum obtained from patients in the COPD study clinic was assessed in a previous study [19] . Fifty-two consecutive sputum samples induced by inhalation of hypertonic saline were compared with spontaneously expectorated sputum collected on the morning of the induction. The paired samples were compared for purulence, viscosity, number of squamous and nonsquamous cells by microscopic examination, fibrinogen level [20] , and culture. No significant difference was observed in cell content, fibrinogen level, or bacterial pathogens isolated. These results indicate that the spontaneously expectorated sputum samples are comparable to induced sputum and reliably reflect the lower respiratory tract milieu.
Further evaluation of the quality of sputum samples collected in this prospective study was performed as part of another study [21] . Fibrinogen (a marker for lower respiratory tract secretions that is absent in saliva [20] ) was measured in sputum supernatants. Sixteen sputum samples that were negative for Haemophilus influenzae in culture were compared with 15 samples that grew H. influenzae before and after the negative cultures from the same patients. There was no difference in the level of fibrinogen between samples with positive or negative culture results [21] . Therefore, the quality of the sputum samples was similar between those that yielded positive or negative culture results. The sputum samples in the present study were collected from the same cohort of patients and processed using the same methods.
The P. aeruginosa reference strain collection consisted of airway isolates from patients who received ventilation and from patients with CF who had P. aeruginosa infection. Forty-nine singular P. aeruginosa isolates were retrieved from 18 ICUs in 8 European countries [22] . The 128 CF isolates were collected from 38 CF centres in 13 European countries.
P. aeruginosa genotyping. P. aeruginosa strains were genotyped by a custom-made microarray following the protocol published elsewhere [22] . Briefly, all 56 targets for hybridization were amplified from P. aeruginosa colony DNA by cycles of multiplex primer extension reactions with Therminator DNA polymerase (New England Biolabs), whereby the nascent strands were randomly labeled by incorporation of biotin-16-dUTP. The multiplex amplificate was hybridized under high stringency with the oligonucleotide microarray of target sequences that were inserted into the bottom of a standard Eppendorf-like microtube. Hybridization signals were detected by colorimetry with streptavidin-horseradish peroxidase conjugate and tetramethyl benzidine. The hybridization signals were then automatically converted to the electronically portable multilocus genotype. Therefore, the genotype of the core genome of a P. aeruginosa strain was represented in hexadecimal code by 13 single-nucleotide polymorphisms (SNPs) at 7 conserved loci and the subtypes of exoU/ exoS and fliC. The selected SNPs are informative with a frequency of at least 15% for the rarer allele in the P. aeruginosa population [23] . The composition of the accessory genome was analyzed with a set of 38 genetic markers that identify 10 genomic islets and 6 types of genomic islands, whereby subtypes of the latter were differentiated by markers that are variably present in the respective genomic island [24] . The relatedness of strains deter-mined by multilocus genotyping was calculated with the eBurst algorithm (http://eburst.mlst.net) [25] .
Association between clinical manifestations and P. aeruginosa polymorphisms. To analyze possible relationships between P. aeruginosa global or single-marker genotypes and their clinical manifestations in COPD, 3 analyses were performed. Details of how these clinical manifestations were defined have been described elsewhere [16] . In the first analysis, the relationship between bacterial genotypes and the presence of an immune response was determined by whole bacterial cell enzyme-linked immunosorbent assay (ELISA). In the second analysis, strains whose acquisition was associated with an exacerbation were differentiated from colonizing strains, and it was tested whether specific genetic variants determined the propensity toward exacerbation.
In the third analysis, the association between specific genetic polymorphisms and the duration of colonization was examined. On the basis of results of cultures and PCR of the P. aeruginosa gene oprF in bacterial pellets, P. aeruginosa strains were divided into persistent, indeterminate, or cleared strains. A strain was defined as cleared when after the last positive culture result the patient was followed up for at least 6 months and the 6 or more collected sputum samples were all negative for oprF. A strain was defined as persistent when it was acquired at least 6 months before the end of the follow-up period and was present in culture through the patient's last clinic visit or when at least 1 sputum sample collected after the last visit with a positive culture result demonstrated the presence of the oprF gene by PCR. Strains acquired from patients !6 months before the last clinic visit or followed up for !6 months after the last visit with a positive culture result were defined as indeterminate.
The association between the distribution of a genetic marker and a specific clinical manifestation was determined by x 2 analysis. As there were a large number of comparisons made, we applied 2 approaches to adjust the P-values for multiple comparisons, namely, the false discovery rate and permutation tests [26] .
RESULTS AND DISCUSSION
P. aeruginosa in longitudinally collected samples. A total of 126 patients with COPD were enrolled and followed up prospectively during a 10 year, 9 month period from April 1994 through December 2004. Patients made 5100 clinic visits, at which 4552 sputum samples were collected. A total of 230 sputum cultures (5.1%) grew P. aeruginosa [18] . Thirty-nine patients had at least 1 P. aeruginosa-positive sputum culture.
Molecular infection epidemiology. The typing of 134 P. aeruginosa COPD isolates with the microarray uncovered 60 unrelated SNP genotypes (clones) (Figure 1 ). Twenty-five of the 39 P. aeruginosa-positive patients with COPD had acquired only a single P. aeruginosa clone during the 10-year observation period. Two clones were recovered from 9 patients, 3 clones from 4 patients, and 5 clones from 1 patient (Figure 1) . Singular isolates were retrieved from 11 patients, and sequential isolates were collected from the other 28 patients with COPD. Co-colonization with 2 P. aeruginosa clones was observed in 3 patients. In all other patients with 2 or more clones, a sequential turnover of clones was observed. In 8 of these 11 patients there was a gap between the disappearance of the previous clone and the emergence of the next clone. Thus, sporadic or intermittent infection with P. aeruginosa was typical for the airways of patients with COPD. This behavior is different from that of airways of patients with CF. Once P. aeruginosa has taken residence in the lungs of patients with CF, it is notoriously resistant to eradication [27, 28] .
Population biology. Forty of the 60 clones had already been detected in our previously typed P. aeruginosa strain panel obtained from a broad spectrum of environmental and clinical habitats of diverse geographic origin [22] . Of the 20 as-yet undescribed clones, 5 were observed in 2 patients with COPD each; all other novel clones were isolated from just 1 patient, indicating that these novel clones are infrequent in the P. aeruginosa population.
The 16 most abundant clones that made up 50% of the global P. aeruginosa population [22] occurred at a frequency of 37% in the COPD strain panel. The most dominant worldwide clones-PA14 [29] and C [27]-were also the most abundant clones among the COPD isolates ( Figure 1) .
Next, we compared the distribution of P. aeruginosa clones in the airways of patients with COPD with those in the airways of in chronically infected patients with CF and the lungs of acutely infected patients receiving ventilation at ICUs, whereby in all 3 groups each clone was counted only once per patient (Figure 2 ). Despite the disparate geographic origin of the isolates (all CF and ICU isolates were collected in Europe and all COPD isolates were collected in North America), many clones were shared by 2 or all 3 patient populations ( Figure 2A ). The dominant P. aeruginosa clones were found with similar frequencies in acutely and chronically infected respiratory tracts irrespective of the etiology of disease. There were numerous clones that were retrieved only from patients with COPD, patients with CF, patients receiving ventilation (Figure 2 ). These clones, however, were all rare, being either singletons or doublets, indicating that these data do not support an association between clone and a specific lung disease.
The spectrum of the typed COPD isolates covers a large part of the current P. aeruginosa population. The eBurst diagram ( Figure 2B ) shows the population structure of P. aeruginosa, whereby isolates from patients with COPD, patients with CF, and patients receiving ventilation are highlighted. No prominent disease-associated clones were detected.
Bacterial genotype and disease phenotype. Next, we asked . Clonal complexes were calculated from the 15-marker genotype of the core genome by the eBurst algorithm [25] . B, Clonal complex structure of P. aeruginosa strains collected from diverse habitats and geographic origins. Clonal complexes contain airway isolates from patients with COPD (red), patients with CF (blue), patients receiving ventilation (yellow), patients with COPD and CF (magenta), patients with COPD and patients receiving ventilation (orange), patients with CF and patients receiving ventilation (green), and all 3 patient groups (black). Genotypes that to date have been observed only in other habitats [22] are depicted in gray. The size of the symbol indicates the number of typed strains with the same genotype. Clones C [27] and PA14 [29] are the most abundant clones in the global P. aeruginosa population [22] .
whether any association exists between P. aeruginosa genotype and the clinical manifestations in the patients with COPD. None of the global or single-marker genotypes were associated with the development of an immune response or the occurrence of an exacerbation with acquisition of the strain. Thus, the P. aeruginosa clones that had been retrieved from COPD-affected airways were comparably proficient to cause an exacerbation or to evoke a systemic humoral immune response. It remains to be seen whether these clones are a representative sample of the global bacterial population or whether they represent a subset of clones that are endowed with a higher fitness to colonize the damaged airways of a host with COPD. Microevolution of the P. aeruginosa accessory genome in COPD. The accessory genome is made up of genomic islets and islands [24] . The largest islands-namely, P. aeruginosa genomic islands 1 (PAGI-1) and 2 (PAGI-2) and pKLC102-were present at frequencies of 80%, 57%, and 71%, respectively, in the COPD strain collection (Figure 1) . The microarray differentiated 11 PAGI-2 subtypes and 16 pKLC102 subtypes. Thus, the incidence and diversity of the large islands were comparable to those of the global population [22] .
Sequential isolates with the same genotype of the core genome were recovered from 26 patients with COPD. Ten clonal strains from 9 patients showed a change in their makeup of the accessory genome. Intraclonal diversity was significantly more often observed if more sequential isolates of the particular clone were available for analysis ( , Mann-Whitney P ! .001 U test), indicating that a P. aeruginosa clone diversifies its accessory genome if it persists for a long period of time in the airways of patients with COPD.
Most strikingly, several clones diversified in their repertoire of large genomic islands. PAGI-1 has no transfer RNA (tRNA) integration site [30] and has been considered a stably integrated insertion. Unexpectedly, variable carriage of PAGI-1 was found in sequential clonal variants from 3 patients, suggesting that either PAGI-1-positive or PAGI-1-negative variants were coexisting and/or that PAGI-1 could be reversibly mobilized from the chromosome. Both scenarios have not yet been reported in the literature, to our knowledge.
In contrast to PAGI-1, islands of the PAGI-2 type are known to be excised from the chromosome and transferred to a recipient even across species barriers, albeit at a frequency of 10 Ϫ8 or less [31] . Considering the low mobility of PAGI-2 islands, it is noteworthy that the clonal variants from COPD patient 100 were carrying different PAGI-2 subtypes.
At present, PKLC102 is the most mobile genomic island known [31] . pKLC102 is excised from and reintegrated into the bacterial chromosome at frequencies of 5% or more per generation [31] . Hence, we could expect the coexistence of pKLC102-positive and -negative strains in a set of sequential isolates from an individual COPD-affected respiratory tract (Figure 1 ). The detection of 2 or even 3 different pKLC102 subtypes among the clonal variants from an individual patient, however, was surprising. This clonal microevolution in the genetic makeup of pKLC102 islands was seen in sequential isolates from 3 patients. The most pronounced intraclonal variation was observed in COPD patient 101, who was chronically harboring the abundant P. aeruginosa clone 3C2A in the airways (Figure 1 ). Genotyping of the 12 isolates identified 3 pKLC102 and 2 PAGI-2 subtypes and the variable presence of PAGI-1 and 4 genomic islets. Uptake and loss of islands by horizontal gene transfer probably drove the extensive adaptive radiation of the clone in this patient.
COPD-associated genetic signatures. The exoS and exoU genes encoding type III secretion virulence effector proteins are mutually exclusive in the P. aeruginosa genome [32] . The exoUpositive strains were underrepresented in COPD isolates (13%) compared with the global P. aeruginosa population (22%) ( ; ) [22] . ExoU is a potent cytotoxin [33] , and 2
x p 4.46 P ! .05 ExoU-mediated destruction of lung tissue is probably incompatible with chronic bacterial colonization that requires some maintenance of the niche, which reasonably explains the low frequency of exoU-positive P. aeruginosa strains in COPD-affected airways. Pyoverdines are iron(III) chelators and signal molecules for the production of virulence factors. Pyoverdine outer membrane type I FpvA receptors dominated in the global population as well as in isolates from COPD-affected lungs, whereas isolates from CF lungs carried all FpvA receptor types at a similar frequency ( ) (Figure 3 ). The distribution of FpvA re-P ! .01 ceptors, however, differed by the duration of colonization in COPD-affected lungs. Strains with fpvA_type I were overrepresented in the panel of sporadic isolates, but strains with fpvA_type IIb ( ) or fpvA_type III ( ) [34] were P ! .05 P ! .001 comparatively more frequent among the panel of persisters in COPD-affected lungs.
The gene pKL-3 ( ) was the other locus that showed P ! .001 a statistically significant association with the duration of colonization by P. aeruginosa in COPD. pKL-3 and fpvA represent the hot spots of microevolution in the core and accessory genomes. pKL-3 is present in all mobile gene islands of the pKLC102 family and is a marker for genome mobility and horizontal gene transfer [31] . The pyoverdine outer membrane receptor fpvA belongs to the most divergent region of the core genome, shows substantial intratype variation, and is the only known P. aeruginosa gene that evolves under positive selection [35] . Thus, the 2 loci that evolve at the highest rate in the P. aeruginosa genome were identified as diagnostic for the longterm persistence of P. aeruginosa in the atypical niche of COPDaffected airways.
P. aeruginosa infections in COPD and CF: more disparities than similarities. The purifying selection at these 2 loci indicates that some genetic adaptation of P. aeruginosa takes place during chronic colonization of COPD-affected airways. Martínez-Solano et al [15] recently reported studies of P. aeruginosa isolates from 13 patients with COPD. In comparison with isolates from blood culture, the COPD isolates generally showed an increased mutation rate, increased antibiotic resistance, reduced production of proteases, less cytotoxicity, less motility, and greater biofilm production [15] . This phenotypic signature is typical for P. aeruginosa isolates from chronically colonized lungs of patients with CF [36] . On the basis of their results, Martínez-Solano et al [15] suggest that P. aeruginosa may cause chronic infections in patients with COPD that are similar to those seen in patients with CF. However, a caveat in placing these novel observations in context is that these 13 patients with COPD represent a selected subset. Our data from the 10-year prospective study demonstrate that the majority of patients were harboring P. aeruginosa in their airways for only a short time (Figure 1) . If patients were colonized with P. aeruginosa for months or years, a sequential turnover of clones was observed. Only 7 patients were persistently colonized with the same P. aeruginosa clone for years, similar to the patients described by Martínez-Solano et al [15] . In contrast, 60% of the chronically colonized patients with CF at the CF clinic in Hannover were still harboring the initially acquired P. aeruginosa clone after 20 years of colonization (N. Cramer, unpublished data). These data indicate that the carriage patterns of P. aeruginosa are different in CF and COPD.
Likewise, the effect of P. aeruginosa on outcome is different. Chronic P. aeruginosa airway infections are the major cause of morbidity and mortality in CF [1] [2] [3] . By contrast, P. aeruginosa colonization occurs in only a minority of patients with COPD, and many of these episodes are transient colonizations. Consequently, the aggressive antipseudomonal treatment is one of the hallmarks of treatment in CF [1, 3] , whereas we still lack proof that patients would benefit from antimicrobial therapy directed at P. aeruginosa infection in the context of COPD [9] .
Conclusion. In summary, airway infections with P. aeruginosa in patients with COPD are characterized by repeated cycles of the acquisition and clearance of clones. Chronic carriage of a clone was observed in a minority of investigated patients. If a clone chronically persisted in COPD-affected lungs for an extended period of time, the clone often changed the repertoire of its accessory genome. Hence, intraclonal microevolution and the frequent turnover or loss of clones are typical of infections with P. aeruginosa in COPD. This epidemiological signature is divergent from that of the chronic P. aeruginosa infections in patients with CF, the latter being characterized by no or slow turnover of clones [27, 28] .
